Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Josef S Smolen, Daniel Aletaha
Nature Reviews Rheumatology (2015) Vol. 11, Iss. 5, pp. 276-289
Closed Access | Times Cited: 433

Showing 1-25 of 433 citing articles:

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen, Robert Landewé, Johannes Bijlsma, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 6, pp. 960-977
Open Access | Times Cited: 5210
Rheumatoid arthritis
Josef S Smolen, Daniel Aletaha, Iain B. McInnes
The Lancet (2016) Vol. 388, Iss. 10055, pp. 2023-2038
Open Access | Times Cited: 3736
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 685-699
Open Access | Times Cited: 2326
Rheumatoid arthritis
Josef S Smolen, Daniel Aletaha, Anne Barton, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Closed Access | Times Cited: 1875
Diagnosis and Management of Rheumatoid Arthritis
Daniel Aletaha, Josef S Smolen
JAMA (2018) Vol. 320, Iss. 13, pp. 1360-1360
Closed Access | Times Cited: 1701
Immunopathogenesis of Rheumatoid Arthritis
Gary S. Firestein, Iain B. McInnes
Immunity (2017) Vol. 46, Iss. 2, pp. 183-196
Open Access | Times Cited: 994
Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis
Qiangzhe Zhang, Diana Dehaini, Yue Zhang, et al.
Nature Nanotechnology (2018) Vol. 13, Iss. 12, pp. 1182-1190
Closed Access | Times Cited: 787
Distinct fibroblast subsets drive inflammation and damage in arthritis
Adam P. Croft, Joana Campos, Kathrin Jansen, et al.
Nature (2019) Vol. 570, Iss. 7760, pp. 246-251
Open Access | Times Cited: 740
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese, Joel Kremer, Omid Zamani, et al.
New England Journal of Medicine (2016) Vol. 374, Iss. 13, pp. 1243-1252
Open Access | Times Cited: 550
Cytokines in rheumatoid arthritis — shaping the immunological landscape
Iain B. McInnes, Christopher D. Buckley, John D. Isaacs
Nature Reviews Rheumatology (2015) Vol. 12, Iss. 1, pp. 63-68
Closed Access | Times Cited: 451
The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting
Vivianne Malmström, Anca I. Catrina, Lars Klareskog
Nature reviews. Immunology (2016) Vol. 17, Iss. 1, pp. 60-75
Closed Access | Times Cited: 386
Methotrexate an Old Drug with New Tricks
Yosra Bedoui, Xavier Guillot, Jimmy Sélambarom, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 20, pp. 5023-5023
Open Access | Times Cited: 363
Tailoring Materials for Modulation of Macrophage Fate
Jinhua Li, Xinquan Jiang, Hongjun Li, et al.
Advanced Materials (2021) Vol. 33, Iss. 12
Open Access | Times Cited: 291
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Qian Ding, Wei Hu, Ran Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 214
Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation
Mauro Perretti, Xavier Leroy, Elliot J. Bland, et al.
Trends in Pharmacological Sciences (2015) Vol. 36, Iss. 11, pp. 737-755
Open Access | Times Cited: 194
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis
Maya H Buch, Stephen Eyre, Dennis McGonagle
Nature Reviews Rheumatology (2020) Vol. 17, Iss. 1, pp. 17-33
Closed Access | Times Cited: 191
Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Roy Fleischmann, Janet van Adelsberg, Yong Lin, et al.
Arthritis & Rheumatology (2016) Vol. 69, Iss. 2, pp. 277-290
Open Access | Times Cited: 173
Secreted Protein Acidic and Rich in Cysteine Mediated Biomimetic Delivery of Methotrexate by Albumin-Based Nanomedicines for Rheumatoid Arthritis Therapy
Lu Liu, Fanlei Hu, Hui Wang, et al.
ACS Nano (2019) Vol. 13, Iss. 5, pp. 5036-5048
Open Access | Times Cited: 150
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
Xue Li, Xinning Tong, Winnie Wan Yin Yeung, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 4, pp. 564-568
Open Access | Times Cited: 108
Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies
Qin Wang, Xianyan Qin, J. Fang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 5, pp. 1158-1174
Open Access | Times Cited: 107
Matrix metalloproteinases in arthritis: towards precision medicine
Bernard Grillet, Rafaela Vaz Sousa Pereira, Jo Van Damme, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 6, pp. 363-377
Closed Access | Times Cited: 97
Nanoenzyme engineered neutrophil-derived exosomes attenuate joint injury in advanced rheumatoid arthritis via regulating inflammatory environment
Lei Zhang, Ziguo Qin, Han Sun, et al.
Bioactive Materials (2022) Vol. 18, pp. 1-14
Open Access | Times Cited: 91
DNA Origami as a Nanomedicine for Targeted Rheumatoid Arthritis Therapy through Reactive Oxygen Species and Nitric Oxide Scavenging
Yuxuan Ma, Zhangwei Lu, Bin Jia, et al.
ACS Nano (2022) Vol. 16, Iss. 8, pp. 12520-12531
Open Access | Times Cited: 83
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
Jay Tuttle, Edit Drescher, Jesus Abraham Simón Campos, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 20, pp. 1853-1862
Closed Access | Times Cited: 67
A DNA origami device spatially controls CD95 signalling to induce immune tolerance in rheumatoid arthritis
Ling Li, Jue Yin, Wen Ma, et al.
Nature Materials (2024) Vol. 23, Iss. 7, pp. 993-1001
Closed Access | Times Cited: 35
Page 1 - Next Page

Scroll to top